Infectious Disease Treatment Market By Application (AIDS, Chlamydia Trachomatis And Neisseria Gonorrhoeae (CT/NG), Hepatitis B, Hepatitis C, Human Papillomavirus (HPV) Infection, Methicillin-Resistant Staphylococcus Aureus (MRSA) Hospital Acquired Infection, Tuberculosis (TB)), By End User (Academics, Hospitals Laboratories, Physician Office Labs, Reference Labs), By Technique (Molecular Diagnostics, Traditional Diagnostic Techniques), By Product (Consumables, Instruments & Analyzers, Services & Software’s) , Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jun 16, 2016

Key Findings


The global infectious disease treatment market is expected to grow with an impressiveCAGR of 8.2% during the forecasted period of 2015-2022. The major factors contributing towards the growth ofmarket isescalating incidences of infectious diseases in the global market. HIV is the major health issue across the globe, according to WHO, in 2014 around 34 million people claimed it and around 1.6 million people died dueto HIV globally. However, in 2014 around 9.6 million people sufferedby TB and around 1.5 million people died due to TB during 2014. 95% of TB death occurs in middle income and low income countries. The TB is one of the major cause for the death of women aged15 to 44. While around 1 million children fall ill by TB out of which approx. 140,000 children died by this infectious disease. However, TB is the major reason for the death of HIV patients, 1 on 3 HIV patients died due to TB.

The hepatitis B is also one of the major infectious disease around 240 million people are chronically infected by thisdiseases, out of which around 780,000 people die every year due to prevalence of hepatitis B. The global infectious disease treatment market is growing undoubtedly but there are certain factors which are restraining the growth of market such as novel techniques & deferment authorizations of new diagnostic tests and high healthcare cost etc. The growing demand in emerging market, increasing research and development initiatives and rising demand for personalized medicine are the key opportunities available in the global market. The rising prevalence of infectious diseases in Asia Pacific region is tha major factor that is uplifting the growth and creating the opportunities in the global market for the forecasted period.


Market Segment Insight


The global infectious disease treatment market is segmented into end user, application, product, technique and geography. On the basis of end user, the market is segmented into hospitals laboratories, reference labs, physician office labs, academics, others, the academic end users include academic medical centers/research labs and university labs and other end user include blood banks, local public health laboratories, home health agencies, nursing homes, point of care, self-testing. The product segment is categorizedinto instruments & analyzers, consumables, services & software’s.The application segment has beensegmented into Hepatitis B, Hepatitis C, Aids, Tuberculosis (TB), Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG), Human Papillomavirus (HPV) Infection, Methicillin-Resistant Staphylococcus Aureus (MRSA) Hospital Acquired Infection and Others whereas the other segment further bifurcated into influenza, ebola, typhoid, malaria and dengue. Technique is also segmented into traditional diagnostic techniques and molecular diagnostics. Traditional diagnostic technique is sub divided into immunodiagnostics, microscopy and biochemical characterization. The molecular diagnostics market is further segmented into PCR, INAAT, Hybridization, DNA sequencing & ngs, microarray and others. Human papillomavirus (HPV) and hospital-acquired MRSA infections segments are projected to grow with a remarkable CAGR during the forecasted period. The growth in these segments is attributed by the rising prevalence of infectious diseases across the globe in recent years. PCR and INAAT anticipated to largest segment in the global market.


Regional Insight


Globally, the infectious disease treatment market is segmented intoNorth America, Europe, APAC and ROW. North America region holds the largest market share in the global infectious diseases market followed by Europe. The dominance is being driven by the increasing prevalence rate of infectious diseases and the presence of major key players who are spending a huge amount on the research and development of the new technology. However, Asia Pacific region is anticipated to grow with the highest CAGR of 10% during the forecasted period in the global market.The growth in the region is majorly driven by increasing prevalence of HIV, tuberculosis and hepatitis in the Asia Pacific countries such as India, China, Japan and Australia. However, there are various awareness initiatives run by government in such countries which are also promoting the market growth.


Competitive Insights


Some of the market players are Abbott Laboratories, Bio-Rad Laboratories, Cipla, Danaher Corporation, GlaxoSmithKline, IPCA Laboratories, Johnson and Johnson, Novartis International, Pfizer, Roche Diagnostics, Siemens Healthcareetc. Acquisitions, mergers, product development, joint ventures and expansions are the key strategies adopted by the market players to sustain in the market.On 27th March 2015, Johnson & Johnson has announced its collaboration with Google for the purpose of advance surgical robots. This collaboration helps in benefiting patients, surgeons and healthcare systems.

CHAP 1. METHODOLOGY & SCOPE 12
1.1. RESEARCH METHODOLOGY 12
1.2. RESEARCH SCOPE & ASSUMPTIONS 12
1.3. LIST OF DATA SOURCES 12


CHAP 2. EXECUTIVE SUMMARY 13
2.1. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET SUMMARY & KEY BUYING CRITERIA 13
2.2. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET OUTLOOK 13
2.3. MARKET SEGMENTATION ANALYSIS 13
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 13
2.5. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET VALUE CHAIN ANALYSIS 13
2.6. VENDOR LANDSCAPE 13


CHAP 3. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET 14
3.1. MARKET DRIVER ANALYSIS 14
3.1.1. HIGH PREVALENCE RATE OF INFECTIOUS DISEASES 14
3.1.2. SLOW TURNAROUND TIME CREATES DEMAND FOR RAPID DIAGNOSTIC PROCEDURE 14
3.1.3. ENHANCED MANAGEMENT AND CONTROL OF INFECTIOUS DISEASES 14
3.1.4. AUGMENTED FUNDING 14
3.2. MARKET RESTRAINT ANALYSIS 14
3.2.1. HIGH HEALTHCARE COST RESTRICTS USAGE OF NOVEL TECHNIQUES 14
3.2.2. STRINGENT GOVERNMENT REGULATIONS 14
3.2.3. DEFERMENT AUTHORIZATIONS OF NEW DIAGNOSTIC TESTS 14
3.3. KEY OPPORTUNITIES 14
3.3.1. GROWING DEMAND IN EMERGING MARKET 14
3.3.2. INCREASING RESEARCH AND DEVELOPMENT INITIATIVES 14
3.3.3. RISING DEMAND FOR PERSONALIZED MEDICINE 14
3.4. CHALLENGES 14
3.4.1. LACK OF SKILLED PROFESSIONAL 14
3.4.2. HITCHES REGARDING REIMBURSEMENT POLICIES 14


CHAP 4. INDUSTRY ANALYSIS 15
4.1. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET– PORTER’S FIVE FORCE MODEL 15
4.2. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET– PESTEL ANALYSIS 15
4.3. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET– GAP ANALYSIS 15


CHAP 5. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY APLICATION 2012-2022 ($ MILLION) 16
5.1. GLOBAL AIDS MARKET 2012-2022 ($ MILLION) 16
5.2. GLOBAL CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) MARKET 2012-2022 ($ MILLION) 16
5.3. GLOBAL HEPATITIS B MARKET 2012-2022 ($ MILLION) 16
5.4. GLOBAL HEPATITIS C MARKET 2012-2022 ($ MILLION) 16
5.5. GLOBAL HUMAN PAPILLOMAVIRUS (HPV) INFECTION MARKET 2012-2022 ($ MILLION) 16
5.6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) HOSPITAL ACQUIRED INFECTION MARKET 2012-2022 ($ MILLION) 16
5.7. GLOBAL TUBERCULOSIS (TB) MARKET 2012-2022 ($ MILLION) 16
5.8. GLOBAL OTHER MARKET 2012-2022 ($ MILLION) 16


CHAP 6. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY END USER 2012-2022 ($ MILLION) 17
6.1. GLOBAL ACADEMICS MARKET 2012-2022 ($ MILLION) 17
6.2. GLOBAL HOSPITALS LABORATORIES MARKET 2012-2022 ($ MILLION) 17
6.3. GLOBAL PHYSICIAN OFFICE LABS MARKET 2012-2022 ($ MILLION) 17
6.4. GLOBAL REFERENCE LABS MARKET 2012-2022 ($ MILLION) 17
6.5. GLOBAL OTHER MARKET 2012-2022 ($ MILLION) 17


CHAP 7. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY TECHNIQUE 2012-2022 ($ MILLION) 18
7.1. GLOBAL MOLECULAR DIAGNOSTICS MARKET 2012-2022 ($ MILLION) 18
7.1.1. GLOBAL DNA SEQUENCING & NGS MARKET 2012-2022 ($ MILLION) 18
7.1.2. GLOBAL HYBRIDIZATION MARKET 2012-2022 ($ MILLION) 18
7.1.3. GLOBAL INAAT MARKET 2012-2022 ($ MILLION) 18
7.1.4. GLOBAL MICROARRAY MARKET 2012-2022 ($ MILLION) 18
7.1.5. GLOBAL PCR MARKET 2012-2022 ($ MILLION) 18
7.1.6. GLOBAL OTHERS MARKET 2012-2022 ($ MILLION) 18
7.2. GLOBAL TRADITIONAL DIAGNOSTIC TECHNIQUES MARKET 2012-2022 ($ MILLION) 18
7.2.1. GLOBAL BIOCHEMICAL CHARACTERIZATION MARKET 2012-2022 ($ MILLION) 18
7.2.2. GLOBAL IMMUNODIAGNOSTICS MARKET 2012-2022 ($ MILLION) 18
7.2.3. GLOBAL MICROSCOPY MARKET 2012-2022 ($ MILLION) 18


CHAP 8. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY PRODUCT 2012-2022 ($ MILLION) 19
8.1. GLOBAL CONSUMABLES MARKET 2012-2022 ($ MILLION) 19
8.2. GLOBAL INSTRUMENTS & ANALYZERS MARKET 2012-2022 ($ MILLION) 19
8.3. GLOBAL SERVICES & SOFTWARE’S MARKET 2012-2022 ($ MILLION) 19


CHAP 9. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET REGIONAL OUTLOOK 2012-2022 ($ MILLION) 20
9.1. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY REGION 2012-2022 ($ MILLION) 20
9.2. NORTH AMERICA 20
9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.2.3.1. U.S. 20
9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.2.3.2. CANADA 20
9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.3. EUROPE 20
9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 20
9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 20
9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 20
9.3.3.1. GERMANY 20
9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3.3.2. UK 21
9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3.3.3. FRANCE 21
9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3.3.4. RUSSIA 21
9.3.3.4.1. RUSSIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 21
9.3.3.4.2. RUSSIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 21
9.3.3.5. REST OF EUROPE 21
9.3.3.5.1. ROE MARKET ESTIMATES AND FORECAST2012-2022($MILLION) 22
9.3.3.5.2. ROE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 22
9.4. ASIA PACIFIC 22
9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 22
9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.4.3.1. CHINA 22
9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.4.3.2. INDIA 22
9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 22
9.4.3.3. JAPAN 22
9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 22
9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($MILLION) 22
9.4.3.4. ROAPAC 22
9.4.3.4.1. ROAPAC MARKET ESTIMATES AND FORECASTS 2012-2022($MILLION) 23
9.4.3.4.2. ROAPAC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($MILLION) 23
9.5. REST OF THE WORLD 23
9.5.1. REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
9.5.2. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ MILLION) 23
9.5.3. REST OF THE WORLD MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
9.5.3.1. LATIN AMERICA 23
9.5.3.1.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
9.5.3.1.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23
9.5.3.2. MIDDLE EAST AND AFRICA 23
9.5.3.2.1. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 23
9.5.3.2.2. MIDDLE EAST AND AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ MILLION) 23


CHAP 10. COMPETITIVE LANDSCAPE 24
10.1. ABBOTT LABORATORIES 25
10.1.1. COMPANY OVERVIEW 25
10.1.2. SCOT ANALYSIS 25
10.1.3. PRODUCT BENCHMARKING 25
10.1.4. STRATEGIC INITIATIVES 25
10.2. ALERE, INC. 25
10.2.1. COMPANY OVERVIEW 25
10.2.2. SCOT ANALYSIS 25
10.2.3. PRODUCT BENCHMARKING 25
10.2.4. STRATEGIC INITIATIVES 25
10.3. BECTON, DICKINSON & CO. 25
10.3.1. COMPANY OVERVIEW 25
10.3.2. SCOT ANALYSIS 25
10.3.3. PRODUCT BENCHMARKING 25
10.3.4. STRATEGIC INITIATIVES 25
10.4. BIO-RAD LABORATORIES 25
10.4.1. COMPANY OVERVIEW 25
10.4.2. SCOT ANALYSIS 25
10.4.3. PRODUCT BENCHMARKING 25
10.4.4. STRATEGIC INITIATIVES 25
10.5. CIPLA 25
10.5.1. COMPANY OVERVIEW 25
10.5.2. SCOT ANALYSIS 25
10.5.3. PRODUCT BENCHMARKING 25
10.5.4. STRATEGIC INITIATIVES 25
10.6. DANAHER CORPORATION 25
10.6.1. COMPANY OVERVIEW 25
10.6.2. SCOT ANALYSIS 26
10.6.3. PRODUCT BENCHMARKING 26
10.6.4. STRATEGIC INITIATIVES 26
10.7. GLAXOSMITHKLINE 26
10.7.1. COMPANY OVERVIEW 26
10.7.2. SCOT ANALYSIS 26
10.7.3. PRODUCT BENCHMARKING 26
10.7.4. STRATEGIC INITIATIVES 26
10.8. IPCA LABORATORIES 26
10.8.1. COMPANY OVERVIEW 26
10.8.2. SCOT ANALYSIS 26
10.8.3. PRODUCT BENCHMARKING 26
10.8.4. STRATEGIC INITIATIVES 26
10.9. JOHNSON AND JOHNSON 26
10.9.1. COMPANY OVERVIEW 26
10.9.2. SCOT ANALYSIS 26
10.9.3. PRODUCT BENCHMARKING 26
10.9.4. STRATEGIC INITIATIVES 26
10.10. NOVARTIS INTERNATIONAL 26
10.10.1. COMPANY OVERVIEW 26
10.10.2. SCOT ANALYSIS 26
10.10.3. PRODUCT BENCHMARKING 26
10.10.4. STRATEGIC INITIATIVES 26
10.11. PFIZER 26
10.11.1. COMPANY OVERVIEW 26
10.11.2. SCOT ANALYSIS 26
10.11.3. PRODUCT BENCHMARKING 26
10.11.4. STRATEGIC INITIATIVES 26
10.12. ROCHE DIAGNOSTICS 27
10.12.1. COMPANY OVERVIEW 27
10.12.2. SCOT ANALYSIS 27
10.12.3. PRODUCT BENCHMARKING 27
10.12.4. STRATEGIC INITIATIVES 27
10.13. SIEMENS HEALTHCARE 27
10.13.1. COMPANY OVERVIEW 27
10.13.2. SCOT ANALYSIS 27
10.13.3. PRODUCT BENCHMARKING 27
10.13.4. STRATEGIC INITIATIVES 27
10.14. THERMO FISHER SCIENTIFIC, INC. 27
10.14.1. COMPANY OVERVIEW 27
10.14.2. SCOT ANALYSIS 27
10.14.3. PRODUCT BENCHMARKING 27
10.14.4. STRATEGIC INITIATIVES 27
10.15. VERTEX PHARMACEUTICALS 27
10.15.1. COMPANY OVERVIEW 27
10.15.2. SCOT ANALYSIS 27
10.15.3. PRODUCT BENCHMARKING 27
10.15.4. STRATEGIC INITIATIVES 27

TABLE 1 GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY APLICATION 2012-2022 ($ MILLION) 28
TABLE 2 GLOBAL AIDS MARKET 2012-2022 ($ MILLION) 28
TABLE 3 GLOBAL CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) MARKET 2012-2022 ($ MILLION) 28
TABLE 4 GLOBAL HEPATITIS B MARKET 2012-2022 ($ MILLION) 28
TABLE 5 GLOBAL HEPATITIS C MARKET 2012-2022 ($ MILLION) 29
TABLE 6 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) INFECTION MARKET 2012-2022 ($ MILLION) 29
TABLE 7 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) HOSPITAL ACQUIRED INFECTION MARKET 2012-2022 ($ MILLION) 29
TABLE 8 GLOBAL TUBERCULOSIS (TB) MARKET 2012-2022 ($ MILLION) 29
TABLE 9 GLOBAL OTHERS MARKET 2012-2022 ($ MILLION) 29
TABLE 10 GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY END USER 2012-2022 ($ MILLION) 29
TABLE 11 GLOBAL ACADEMICS MARKET 2012-2022 ($ MILLION) 29
TABLE 12 GLOBAL HOSPITALS LABORATORIES MARKET 2012-2022 ($ MILLION) 29
TABLE 13 GLOBAL PHYSICIAN OFFICE LABS MARKET 2012-2022 ($ MILLION) 29
TABLE 14 GLOBAL REFERENCE LABS MARKET 2012-2022 ($ MILLION) 29
TABLE 15 GLOBAL OTHERS MARKET 2012-2022 ($ MILLION) 29
TABLE 16 GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY TECHNIQUE 2012-2022 ($ MILLION) 29
TABLE 17 GLOBAL MOLECULAR DIAGNOSTICS MARKET 2012-2022 ($ MILLION) 29
TABLE 18 GLOBAL DNA SEQUENCING & NGS MARKET 2012-2022 ($ MILLION) 29
TABLE 19 GLOBAL HYBRIDIZATION MARKET 2012-2022 ($ MILLION) 29
TABLE 20 GLOBAL INAAT MARKET 2012-2022 ($ MILLION) 29
TABLE 21 GLOBAL MICROARRAY MARKET 2012-2022 ($ MILLION) 29
TABLE 22 GLOBAL PCR MARKET 2012-2022 ($ MILLION) 29
TABLE 23 GLOBAL OTHERS MARKET 2012-2022 ($ MILLION) 29
TABLE 24 GLOBAL TRADITIONAL DIAGNOSTIC TECHNIQUES MARKET 2012-2022 ($ MILLION) 29
TABLE 25 GLOBAL BIOCHEMICAL CHARACTERIZATION MARKET 2012-2022 ($ MILLION) 29
TABLE 26 GLOBAL IMMUNODIAGNOSTICS MARKET 2012-2022 ($ MILLION) 30
TABLE 27 GLOBAL MICROSCOPY MARKET 2012-2022 ($ MILLION) 30
TABLE 28 GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET BY PRODUCT 2012-2022 ($ MILLION) 30
TABLE 29 GLOBAL CONSUMABLES MARKET 2012-2022 ($ MILLION) 30
TABLE 30 GLOBAL INSTRUMENTS & ANALYZERS MARKET 2012-2022 ($ MILLION) 30
TABLE 31 GLOBAL SERVICES & SOFTWARE’S MARKET 2012-2022 ($ MILLION) 30
TABLE 32 NORTH AMERICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 30
TABLE 33 NORTH AMERICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY REGION 2012 – 2022 ($ MILLION) 30
TABLE 34 NORTH AMERICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 30
TABLE 35 U.S. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 30
TABLE 36 U.S. GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 30
TABLE 37 CANADA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 30
TABLE 38 CANADA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 –2022 ($ MILLION) 30
TABLE 39 CANADA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 30
TABLE 40 EUROPE GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 30
TABLE 41 EUROPE GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY REGION 2012 – 2022 ($ MILLION) 30
TABLE 42 EUROPE GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 30
TABLE 43 GERMANY GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 44 GERMANY METABOLOMICS TECHNOLOGY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 45 UK GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 46 UK GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 47 ASIA PACIFIC GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 48 ASIA PACIFIC GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY REGION 2012 – 2022 ($ MILLION) 31
TABLE 49 ASIA PACIFIC GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 50 CHINA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 51 CHINA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 52 INDIA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 53 INDIA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 54 JAPAN GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 55 JAPAN GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 56 MIDDLE EAST & AFRICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 57 MIDDLE EAST & AFRICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 31
TABLE 58 LATIN AMERICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ MILLION) 31
TABLE 59 LATIN AMERICA GLOBAL INFECTIOUS DISEASE TREATMENTS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012 – 2022 ($ MILLION) 32

FIGURE 1 MARKET SHARE BY REGIONS 32
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 9 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 10 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 11 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 12 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 13 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32
FIGURE 14 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ MILLION) 32

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)